Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection

Furthermore, repeating clinical trials for each variant might take so long that even newer variants could emerge while these clinical trials are underway. Because the immune responses required to prevent mild disease might be different to severe disease, correlates of protection might need to be str...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2021-04, Vol.397 (10281), p.1263-1264
Main Author: Karim, Salim S Abdool
Format: Article
Language:English
Subjects:
Animal models
Brazil
ChAdOx1 nCoV-19
Clinical trials
Coronaviruses
Correlation
Correspondence
COVID-19
COVID-19 Vaccines
Humans
Immune response
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
South Africa
United Kingdom
Vaccines
Viral Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Furthermore, repeating clinical trials for each variant might take so long that even newer variants could emerge while these clinical trials are underway. Because the immune responses required to prevent mild disease might be different to severe disease, correlates of protection might need to be stratified on the basis of disease severity. [...]studies with multiple vaccines to fast-track the identification of an animal model, assay, or marker as a correlate of protection should be initiated to address gaps in the correlate research plans. [...]a central database should be created to collate data for each of the efficacious vaccines, thereby providing larger sample sizes to assess multiple variables as correlates of protection and to test if a correlate identified in one trial is valid in other trials.
ISSN:0140-6736
1474-547X
1474-547X
DOI:10.1016/S0140-6736(21)00468-2